CLICK HERE to learn more about Kineta's reverse merger with NASDAQ listed Yumanity Therapeutics (YMTX) and registration statement on Form S-4 with the U.S. SEC


The introduction of new immunotherapies into the clinic has significantly improved the prognosis for many cancer patients over the last decade, but the overall response rates remain relatively low in all tumor types. Newer checkpoint inhibitors (CPIs) like PD(L)-1 and CTLA4 have shown overall response rates of approximately 20-30% in clinical studies as a monotherapy.1  There remains a significant unmet need to improve overall and long term survival for cancer patients. New innovation and enhancements to the currently available therapies are urgently needed to address the treatment gaps.

Building next-generation immunotherapies

Kineta is building next generation immunotherapies to address the major challenges with current cancer treatments.  We aim to improve outcomes for cancer patients by solving the problems of cancer resistance.   Our novel drug programs are focused on addressing and correcting immuno-suppression, lack of tumor antigens and exhausted T cells.

Immuno-oncology development platform

Immuno-oncology is the science of re-programming a patient’s immune system to better recognize and attack cancer cells.  Kineta has established a development platform to build next generation immunotherapies by leveraging our expertise and technology in the following areas.

Biology – Platform Page


Technology – Platform Page


Development – Platform Page


1. Acquired Resistance to Immune Checkpoint Inhibitors Adam J. Schoenfeld and Matthew D. Hellmann. Cancer Cell 2020 Apr 13;37(4):443-455.